Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer

IIIB/IIIC/IV Lung Cancer Clinical Trial

Official title: Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-Lymphocyte (PD1-T) Combined With Docetaxel in the Second-line Treatment of IIIB/IIIC/IV Non-small Cell Lung Cancer

Status Recruiting

Clinical Trial Summary

This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous peripheral blood T-lymphocyte (PD1-T) combined with docetaxel in the second-line treatment of IIIB/IIIC/IV non-small cell lung cancer. Half of participants receive PD1-T combined with docetaxel, while the other half will receive docetaxel.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• IIIB/IIIC/IV Lung Cancer
• Lung Neoplasms

• NCT number: NCT03944980
• Study type: Interventional
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Xiubao Ren, MD. PhD.
• Phone: 86-22-23340123
• Email: liangcoh@163.com
• Status: Recruiting
• Phase: Phase 3
• Start date: June 1, 2019
• Completion date: June 1, 2022